<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Biotech License &#187; biotech
biotechnology</title>
	<atom:link href="http://biotechlicense.com/tag/biotechbiotechnology/feed/" rel="self" type="application/rss+xml" />
	<link>http://biotechlicense.com</link>
	<description>Developments from the world of Biotechnology</description>
	<lastBuildDate>Thu, 29 Jul 2010 20:18:41 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>1,2,4-Benzothiadiazine derivatives</title>
		<link>http://pharmalicensing.com/licensing/displicopp/2676</link>
		<comments>http://pharmalicensing.com/licensing/displicopp/2676#comments</comments>
		<pubDate>Fri, 31 Jul 2009 12:02:06 +0000</pubDate>
		<dc:creator>Pharmalicensing.com</dc:creator>
				<category><![CDATA[Biotech Licensing]]></category>
		<category><![CDATA[biotech
biotechnology]]></category>

		<guid isPermaLink="false">http://pharmalicensing.com/licensing/displicopp/2676</guid>
		<description><![CDATA[1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes.]]></description>
			<content:encoded><![CDATA[1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes.]]></content:encoded>
			<wfw:commentRss>http://pharmalicensing.com/licensing/displicopp/2676/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Metabolic profiling methods and compositions to control Warfarin therapy:  personalized medicine for control of coagulation therapy (09-26)</title>
		<link>http://pharmalicensing.com/licensing/displicopp/6485</link>
		<comments>http://pharmalicensing.com/licensing/displicopp/6485#comments</comments>
		<pubDate>Fri, 24 Jul 2009 09:43:09 +0000</pubDate>
		<dc:creator>Pharmalicensing.com</dc:creator>
				<category><![CDATA[Biotech Licensing]]></category>
		<category><![CDATA[biotech
biotechnology]]></category>

		<guid isPermaLink="false">http://pharmalicensing.com/licensing/displicopp/6485</guid>
		<description><![CDATA[Metabolomic assessment of the different Cytochrome P450 and UDP-Glucuronosyltransferase contributions to Warfarin Metabolism in individual patients ]]></description>
			<content:encoded><![CDATA[Metabolomic assessment of the different Cytochrome P450 and UDP-Glucuronosyltransferase contributions to Warfarin Metabolism in individual patients ]]></content:encoded>
			<wfw:commentRss>http://pharmalicensing.com/licensing/displicopp/6485/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Two Pharmas: Better than One</title>
		<link>
              http://www.bio-itworld.com/news/2009/07/24/BP-merck-abbott.html</link>
		<comments>
              http://www.bio-itworld.com/news/2009/07/24/BP-merck-abbott.html#comments</comments>
		<pubDate>Fri, 24 Jul 2009 06:00:00 +0000</pubDate>
		<dc:creator>BioIT Top Headlines</dc:creator>
				<category><![CDATA[Biotech News]]></category>
		<category><![CDATA[biotech
biotechnology]]></category>

		<guid isPermaLink="false">tag:www.bio-itworld.com://d535e301d790622010162cb6e2cdde8d</guid>
		<description><![CDATA[<p><font size="2"><strong>Bio-IT World</strong> &#124; <strong>Best Practices</strong> &#124; Two years ago, Merck and Abbott agreed to explore a consortium approach to building the robust IT infrastructure for registering biological materials. Biological materials require a sophisticated understanding to define them uniquely and the system developed in conjunction with Accelrys solves a host of challenges related to IP protection and knowledge sharing.</font></p>]]></description>
			<content:encoded><![CDATA[<p><font size="2"><strong>Bio-IT World</strong> | <strong>Best Practices</strong> | Two years ago, Merck and Abbott agreed to explore a consortium approach to building the robust IT infrastructure for registering biological materials. Biological materials require a sophisticated understanding to define them uniquely and the system developed in conjunction with Accelrys solves a host of challenges related to IP protection and knowledge sharing.</font></p>]]></content:encoded>
			<wfw:commentRss>
              http://www.bio-itworld.com/news/2009/07/24/BP-merck-abbott.html/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Health Care vs. Biotech</title>
		<link>
              http://www.bio-itworld.com/els/2009/07/24/pharma-buys-biotech.html</link>
		<comments>
              http://www.bio-itworld.com/els/2009/07/24/pharma-buys-biotech.html#comments</comments>
		<pubDate>Thu, 23 Jul 2009 06:00:00 +0000</pubDate>
		<dc:creator>BioIT Top Headlines</dc:creator>
				<category><![CDATA[Biotech News]]></category>
		<category><![CDATA[biotech
biotechnology]]></category>

		<guid isPermaLink="false">tag:www.bio-itworld.com://b8d8cbe56a4a2a94e42e5b00e78a8cdf</guid>
		<description><![CDATA[<p><font size="2"><strong>CNN Money</strong> &#124; Obama's health care reform plan may affect biotech -- driving stock prices up.</font></p>]]></description>
			<content:encoded><![CDATA[<p><font size="2"><strong>CNN Money</strong> | Obama's health care reform plan may affect biotech -- driving stock prices up.</font></p>]]></content:encoded>
			<wfw:commentRss>
              http://www.bio-itworld.com/els/2009/07/24/pharma-buys-biotech.html/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Boosting Adaptive Clinical Trials</title>
		<link>
              http://www.bio-itworld.com/news/2009/07/23/BP-clintrialdesign.html</link>
		<comments>
              http://www.bio-itworld.com/news/2009/07/23/BP-clintrialdesign.html#comments</comments>
		<pubDate>Thu, 23 Jul 2009 06:00:00 +0000</pubDate>
		<dc:creator>BioIT Top Headlines</dc:creator>
				<category><![CDATA[Biotech News]]></category>
		<category><![CDATA[biotech
biotechnology]]></category>

		<guid isPermaLink="false">tag:www.bio-itworld.com://92fe4f01b4c417121258317f532867f2</guid>
		<description><![CDATA[<p><font size="2"><strong>Bio-IT World &#124; Best Practices &#124;</strong> Wyeth Research and partners are developing trial simulation software to streamline the process of designing and running adaptive clinical trials (ACTs). </font></p>]]></description>
			<content:encoded><![CDATA[<p><font size="2"><strong>Bio-IT World | Best Practices |</strong> Wyeth Research and partners are developing trial simulation software to streamline the process of designing and running adaptive clinical trials (ACTs). </font></p>]]></content:encoded>
			<wfw:commentRss>
              http://www.bio-itworld.com/news/2009/07/23/BP-clintrialdesign.html/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
